Clinical outcomes with utilization of high-potency topical steroids in patients with lichen sclerosus-associated vulvar cancer

• Published in: Gynecologic oncology Vol. 187; pp. 58 - 63
• Main Authors: Vue, Nujsaubnusi C., Sassani, Jessica, Prairie, Beth, Yin, Yue, Krivak, Thomas C., Crafton, Sarah, Morse, Christopher, Nakayama, John, Wield, Alyssa, Horne, Zachary D., Miller, Eirwen M.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.08.2024
• Subjects: Administration, Topical; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell - drug therapy; Carcinoma, Squamous Cell - pathology; Clobetasol; Clobetasol - administration & dosage; Cohort Studies; Female; Humans; Lichen Sclerosus; Lichen Sclerosus et Atrophicus - drug therapy; Middle Aged; Neoplasm Recurrence, Local - drug therapy; Recurrence; Retrospective Studies; Treatment Outcome; Vulvar Cancer; Vulvar Lichen Sclerosus - drug therapy; Vulvar Neoplasms - drug therapy; Lichen Sclerosus; Recurrence; Vulvar Cancer; Clobetasol
• ISSN: 0090-8258; 1095-6859; 1095-6859
• DOI: 10.1016/j.ygyno.2024.05.003

To evaluate the impact of high-potency topical steroid use on risk of recurrence of lichen sclerosus-associated vulvar cancer. This is a retrospective cohort study evaluating patients with lichen sclerosus (LS)- associated vulvar squamous cell cancer (VSCC). Demographic and clinical outcome data were compared between two comparison groups: patients who received steroids, mainly clobetasol, and patients who did not receive steroids following treatment of LS-related vulvar cancer. Categorical variables were compared using Fisher's exact test or chi-square test. Continuous variables were compared using a two-sided student's t-test. Time to recurrence (TTR) and overall survival (OS) were analyzed using Kaplan-Meier survival plot and compared using Mantel-Cox log rank test. Cox proportional hazard regression models were conducted to generate hazard ratios for both TTR and OS. A p value of <0.05 was considered statistically significant. A total of 49 patients were included, with 36 patients receiving steroid treatment and 13 patients in the expectant management group. The median age of diagnosis was 68. The average BMI was 31.7 +/− 7.0. The median length of follow up was 41 months. The majority of patients were diagnosed with stage I VSCC. There was no difference in demographics or oncologic management of vulvar cancer between the two cohorts. Overall recurrence was decreased among patients who received steroid treatment when compared to patients who did not, 12 patients (33.3%) versus 9 patients (69.2%) respectively (p = 0.048). High-potency topical steroid use following treatment of lichen sclerosus-associated vulvar squamous cell carcinoma is associated with decreased risk of recurrence and prolonged median time to recurrence. •Lichen sclerosus - associated vulvar cancer carries a worse prognosis when compared with HPV- associated vulvar cancer.•Topical steroids represent standard of care therapy for lichen sclerosus but its impact on vulvar cancer risk is unknown.•High-potency topical steroids may reduce risk of recurrence and prolong recurrence free survival in LS-associated VSCC.